论文部分内容阅读
目的探讨吉西他滨+异环磷酰胺二线用于进展非小细胞肺癌的疗效和不良反应。方法观察吉西他滨联合异环磷酰胺化疗方案治疗非小细胞肺癌铂类基础一线方案进展患者46例,21天为1个周期,每2个周期影像学评价化疗效果,每周期观察化疗反应情况。结果总有效率为39.1%,主要不良反应是骨髓抑制、胃肠道反应,多为Ⅰ～Ⅱ度。结论吉西他滨联合异环磷酰胺方案为二、三线治疗进展非小细胞肺癌的有效方案。
Objective To investigate the efficacy and adverse reactions of gemcitabine + ifosfamide second-line for advanced non-small cell lung cancer. Methods 46 patients with advanced platinum-based first-line regimen of non-small cell lung cancer were treated with gemcitabine combined with ifosfamide chemotherapy regimen. One cycle was performed on 21 days. The chemotherapy effect was evaluated every two cycles. The response to chemotherapy was observed every cycle. Results The total effective rate was 39.1%. The main adverse reactions were myelosuppression and gastrointestinal reactions, mostly Ⅰ ~ Ⅱ degrees. Conclusion The gemcitabine plus ifosfamide regimen is an effective regimen for the treatment of advanced non-small cell lung cancer in the second and third lines.